Trump’s Generic Drug Tariff: What It Means for Indian Pharma Companies

Shares of major Indian pharmaceutical companies fell around 2% to 3% in early trade after US President Donald Trump announced a phased tariff plan for imported generic medicines.

The immediate reaction reflected concerns around the US exposure of Indian drugmakers such as Aurobindo Pharma, Dr Reddy’s Laboratories, Lupin, Zydus Lifesciences, Cipla and Sun Pharma. The US is one of the largest markets for Indian pharmaceutical companies, especially for generic medicines.

However, the proposed tariff does not create an immediate earnings shock. Generic medicines will continue to attract a 0% tariff until July 31, 2028. A 100% tariff is proposed from August 2028, followed by a possible increase to 200% in the next year.

This gives Indian pharma companies around two years to change their manufacturing and supply strategies. The bigger question for investors is whether companies can reduce their dependence on exporting low-cost generic medicines from India before the tariff comes into effect.

What Has Trump Announced on Generic Drug Tariffs?

Trump has proposed a phased tariff structure for generic medicines imported into the US.

This means there is no immediate tariff impact on generic drug exports.

The proposal has currently been announced through Trump’s social media post. A detailed notification explaining product coverage, exemptions, rules of origin and treatment of companies investing in US manufacturing is still awaited.

The absence of these details is important. The final impact will depend on whether the tariffs cover only finished medicines or also include active pharmaceutical ingredients and other pharmaceutical inputs.

Why Is the US Market Important for Indian Pharma Companies?

India is one of the largest suppliers of generic medicines to the US. Indian companies built their US businesses by manufacturing drugs in India, where costs are lower, and exporting them to the American market.

India’s total pharmaceutical exports reached approximately $31.1 billion in FY26. The US accounted for around 34% of these exports.

Based on this share, India exported approximately $10.6 billion worth of pharmaceutical products to the US during the year.

The total export figure shows the scale of India’s dependence on the US market. However, the actual impact on each company will depend on its US revenue contribution, manufacturing location and product mix.

A company exporting simple generic tablets from India faces a different risk compared with a company selling specialty medicines or complex injectable products.

Which Indian Pharma Companies Have the Highest US Exposure?

Several large Indian pharmaceutical companies generate a meaningful share of their revenue from North America.

Aurobindo Pharma generated around ₹14,408 crore of revenue from the US in FY26, compared with total revenue of ₹33,653 crore. A significant part of this portfolio is supplied from facilities located outside the US.

Zydus Lifesciences generated around ₹11,682 crore from North American formulations in FY26. Its US business represents a large share of its pharmaceutical revenue, making it sensitive to any major change in import economics.

Lupin also has high exposure to the US market. However, the company owns a manufacturing facility in New Jersey, which could provide some protection if it shifts more products to local production.

Cipla appears relatively better placed because India remains its largest market and North America contributes a smaller share of total revenue. The company also has manufacturing facilities in the US.

Sun Pharma’s exposure also needs to be viewed differently. A part of its US business comes from specialty and innovative medicines rather than only low-margin generic drugs. Its strong domestic business provides further diversification.

Why Can Indian Drugmakers Not Simply Absorb the Tariff?

Generic medicines are a high-volume but low-margin business.

Generic drugs account for around 90% of prescriptions filled in the US, but only around 13% of total prescription drug spending. This shows that generic medicines are sold at very low prices.

A company earning an operating margin of 10% to 20% cannot absorb a 100% tariff without materially affecting profitability.

The tariff may technically be paid by the US importer. However, large US distributors and buyers may ask Indian manufacturers to reduce their selling prices. This could indirectly transfer part of the tariff burden back to Indian drugmakers.

Companies may respond by increasing prices, but price increases are difficult in the generic drug market because buyers usually have multiple suppliers and strong bargaining power.

This means low-margin products may become commercially unviable if the tariff is implemented without exemptions.

Can Indian Pharma Companies Shift Manufacturing to the US?

Moving manufacturing to the US is one possible solution, but it is not simple.

Indian companies may need to acquire existing manufacturing plants, build new facilities or enter partnerships with US-based contract manufacturers.

However, the cost of producing medicines in the US is significantly higher because of labour, regulatory and operating expenses.

Transferring an existing medicine from an Indian facility to a US plant may also require regulatory approvals, equipment validation, stability testing and fresh inspections.

Therefore, a company owning one US plant does not mean that its entire US portfolio is protected.

Companies with existing US facilities, strong cash flows and healthy balance sheets will be in a better position to shift production. Smaller exporters may find the investment difficult to justify.

Could the Tariff Create Drug Shortages in the US?

The possibility of medicine shortages could become a major challenge for the US administration.

Many older generic drugs are already manufactured by a small number of companies because prices and margins are low. If tariffs make these products unprofitable, manufacturers may discontinue them or withdraw from the market.

The US already faces shortages in several medicines due to manufacturing disruptions, quality concerns and product discontinuations.

A steep tariff could make this situation worse, especially for essential medicines where alternative suppliers are limited.

This could eventually lead to exemptions for essential drugs, medicines already facing shortages or products with very few approved manufacturers.

Companies committing to US manufacturing investments may also seek tariff relief. However, no such exemptions have been confirmed yet.

Which Indian Pharma Companies May Be Better Positioned?

The companies likely to be relatively better positioned are those with a strong domestic business, existing US manufacturing capacity and a larger share of complex or differentiated products.

Complex generics, inhalers, injectable medicines, biosimilars and specialty drugs are generally harder to replace than simple oral tablets. They also usually offer better margins.

Sun Pharma may be better placed because of its specialty portfolio and strong India business. Cipla also has a lower dependence on North America compared with some peers and has existing US facilities.

Companies such as Aurobindo, Lupin, Zydus and Dr Reddy’s have meaningful US exposure. However, their actual risk will depend on how much of their portfolio is manufactured outside the US and whether they can shift production before August 2028.

What Should Investors Track Next?

The first thing investors should watch is the official US notification.

The notification should clarify whether the tariff applies only to finished generic medicines or also covers active pharmaceutical ingredients and intermediate products.

The second important factor is whether the US provides exemptions for essential medicines, shortage drugs or companies investing in local manufacturing.

Investors should also watch for announcements from Indian companies related to US acquisitions, manufacturing partnerships and product transfers.

Capital expenditure will become another key indicator. Companies may need to spend more to expand their US manufacturing presence, which could affect cash flow and return ratios.

Product mix will also become more important. Companies with a higher share of complex and differentiated products may have more pricing power and a better ability to handle higher costs.

Author’s Take

The 2% to 3% decline in major Indian pharma stocks reflects uncertainty around the future of their US businesses. However, the proposed tariff is unlikely to affect near-term earnings because generic medicines will remain tariff-free until July 2028.

The bigger risk is structural. Indian pharma companies have built their US businesses around low-cost manufacturing in India. A 100% or 200% tariff could weaken this model and force companies to shift production to the US, acquire local plants, enter manufacturing partnerships or move towards more complex products.

The two-year window gives companies time to respond, but adapting will require capital, regulatory approvals and higher operating costs.

For investors, the key question is not whether the tariff affects FY27 earnings. It is which Indian pharma companies can protect their US businesses before the tariff begins in August 2028.